"IDH Status Predicts Benefit From PCV With Radiation Therapy in Anaplastic Oligodendroglioma (RTOG 9402)" by G. Cairncross

Selected Works of Minesh Mehta

Follow Contact

Article

IDH Status Predicts Benefit From PCV With Radiation Therapy in Anaplastic Oligodendroglioma (RTOG 9402)

International Journal of Radiation Oncology Biology Physics (2012)

G. Cairncross, University of Calgary
M. Wang, Radiation Therapy Oncology Group
R. Jenkins, Mayo Clinic
E. Shaw, Wake Forest Baptist Medical Center
C. Giannini, Mayo Clinic
D. Brachman, St. Joseph's Hospital and Medical Center
J. Buckner, Mayo Clinic
K. Fink, Baylor University
M. Mehta, Northwestern University
W. Curran, Emory University

Link

Disciplines

Radiology and
Medicine and Health Sciences

Publication Date

January 11, 2012

DOI

10.1016/j.ijrobp.2012.07.018

Citation Information

G. Cairncross, M. Wang, R. Jenkins, E. Shaw, et al.. "IDH Status Predicts Benefit From PCV With Radiation Therapy in Anaplastic Oligodendroglioma (RTOG 9402)" International Journal of Radiation Oncology Biology Physics Vol. 84 Iss. 3 (2012)
Available at: http://works.bepress.com/minesh-mehta/311/